BioCryst Reports Fourth Quarter & Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- US stock futures rise after previous session's selloff
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Noble Affirms BioCryst Pharma (BCRX) at 'Buy' Following Q4 Results; Two Oral HAE Programs Moving Forward
February 24, 2016 11:57 AM ESTNoble Financial affirms BioCryst Pharma (Nasdaq: BCRX) with a Buy rating and $8 price target after the company reported... More
BioCryst Pharma (BCRX) Tops Q4 EPS by 1c
February 23, 2016 7:21 AM ESTBioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.34 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
... More